Comorbidities Affect Risk of Nonvariceal Upper Gastrointestinal Bleeding

Abstract

Background & AimsThe incidence of upper gastrointestinal bleeding (GIB) has not been reduced despite the decreasing incidence of peptic ulcers, strategies to eradicate Helicobacter pylori infection, and prophylaxis against ulceration from nonsteroidal anti-inflammatory drugs. Other factors might therefore be involved in the pathogenesis of GIB. Patients with GIB have increasing nongastrointestinal comorbidity, so we investigated whether comorbidity itself increased the risk of GIB.MethodsWe conducted a matched case-control study using linked primary and secondary care data collected in England from April 1, 1997 through August 31, 2010. Patients older than 15 years with nonvariceal GIB (n = 16,355) were matched to 5 controls by age, sex, year, and practice (n = 81,636). All available risk factors for GIB were extracted and modeled using conditional logistic regression. Adjusted associations with nongastrointestinal comorbidity, defined using the Charlson Index, were then tested and sequential population attributable fractions calculated.ResultsComorbidity had a strong graded association with GIB; the adjusted odds ratio for a single comorbidity was 1.43 (95% confidence interval [CI]: 1.35–1.52) and for multiple or severe comorbidity was 2.26 (95% CI: 2.14%–2.38%). The additional population attributable fraction for comorbidity (19.8%; 95% CI: 18.4%–21.2%) was considerably larger than that for any other measured risk factor, including aspirin or nonsteroidal anti-inflammatory drug use (3.0% and 3.1%, respectively).ConclusionsNongastrointestinal comorbidity is an independent risk factor for GIB, and contributes to a greater proportion of patients with bleeding in the population than other recognized risk factors. These findings could help in the assessment of potential causes of GIB, and also explain why the incidence of GIB remains high in an aging population.

Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study

“…Elderly patients often have more comorbidities and polypharmacy, which are associated with higher bleeding risk than those without 28, 29, 30, 31. Our study agreed with a meta‐analysis of 4 major clinical trials of NOAC with improved efficacy in S/SE (relative risk: 0.81; 95% CI, 0.73–0.91; P <0.0001) and all‐cause mortality (relative risk: 0.90; 95% CI, 0.85–0.95; P <0.0001) and increased gastrointestinal bleeding (relative risk: 1.25; 95% CI, 1.01–1.55; P =0.04) when NOAC prescription was compared with warfarin 32.…”

The CPRD and the RCGP: building on research success by enhancing benefits for patients and practices

“…8 Further, a large study in 123 practices on IBS demonstrated the extensive physical (a range of problems including asthma and symptoms of urinary tract infection) and psychological (namely anxiety and depression) comorbidities associated with IBS. 9 These studies have implications for the cprd and the rcgp:…”

Bioequivalence of diclofenac sodium 2% and 1.5% topical solutions relative to oral diclofenac sodium in healthy volunteers

“…However, orally administered NSAIDs are associated with serious and potentially fatal gastrointestinal and cardiovascular complications. Risks of these complications are increased in patients with comorbidities, the elderly, and in patients taking certain other medications including, but not limited to, antithrombotic agents, corticosteroids, and selective serotonin reuptake inhibitors [4,5]. In particular, elderly patients are at risk of serious toxicity from systemically administered NSAIDs.…”